Pooled study data showed satralizumab for the treatment of neuromyelitis optica spectrum disorder was well tolerated as monotherapy or in combination with immunosuppressive therapy, according to a press release.
The pooled data from the double-masked periods of the SAkuraStar and SAkuraSky phase 3 studies, presented virtually at the European Academy of Neurology meeting, showed rates of adverse events and serious adverse events were comparable between satralizumab and placebo groups when satralizumab was used as monotherapy or in combination with baseline immunosuppressive therapy.
Uncategorized